Arbutus Biopharma (ABUS) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts ABUS Hot Sheet
Join SI Premium – FREE
Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $450 thousand.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent posts a blowout Q4 and aggressive guidance, yet shares take a 5% haircut
- Perma-Fix (PESI) Misses Q2 EPS by 15c
- Talphera (TLPH) Reports In-Line Q2 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
